Conditions Warranting Earlier Repeat Calcium Scoring

Risk-Based Rescanning Intervals

Diabetic patients should undergo repeat CAC at 3 years, particularly those with initial CAC scores of 101-400, as recommended by the American College of Cardiology 1, 2
High-risk patients (≥20% 10-year ASCVD risk) warrant repeat scanning at 3 years, according to the American College of Cardiology 1, 3
Patients with CAC ≥100 and LDL-C ≥70 mg/dL should have repeat CAC at 3 years to assess for accelerated progression (>20-25% per year) or increase to CAC >300, as suggested by the American College of Cardiology 1, 2, 3
Borderline to intermediate-risk patients (5-19.9% 10-year risk) with CAC = 0 warrant repeat scanning in 3-5 years, as recommended by the American College of Cardiology 1, 2, 3
Patients with CAC 1-99 should have repeat scoring in 3-5 years if results might change treatment decisions, according to the American College of Cardiology 1, 2, 3
Any patient with CAC >0 where progression would support intensification of preventive management should be rescanned every 3-5 years, as suggested by the American College of Cardiology 1, 2, 3
Low-risk patients (<5% 10-year risk) with CAC = 0 can wait 5-7 years for repeat scanning, as recommended by the American College of Cardiology 1, 2, 3

Patients with CAC = 0 who deferred pharmacotherapy should be reconsidered for repeat scanning in 3-5 years, especially if they have active smoking, diabetes, chronic inflammatory conditions, or family history of premature CAD, as suggested by the Canadian guidelines 4, 5
Canadian guidelines specifically recommend repeat scans after CAC = 0 when personal risk factors are present or pharmacotherapy is deferred, according to the Canadian guidelines 1, 2
Patients with CAC = 0 but persistent risk-enhancing factors warrant earlier rescanning consideration, as recommended by the American Heart Association 5, 6
Persistent cigarette smoking - CAC = 0 does not rule out risk from noncalcified plaque in active smokers, according to the American Heart Association 5, 6
Family history of premature ASCVD - particularly concerning in younger patients, as suggested by the American Heart Association 5, 6
Chronic inflammatory conditions (rheumatoid arthritis, psoriasis) - CAC = 0 does not exclude increased thrombotic risk, according to the American Heart Association 5, 6
Metabolic syndrome - increases progression risk despite initial zero score, as recommended by the American Heart Association 5, 6

Patients with CAC >400 may not require repeat CAC screening, as these patients are often symptomatic and already vigorously treated, according to the American College of Cardiology 1, 2, 3

Do not down-classify risk in patients with CAC = 0 who are persistent smokers, have diabetes, have family history of ASCVD, or have chronic inflammatory conditions - these patients may still harbor noncalcified plaque or increased thrombotic risk despite zero calcium, as recommended by the American Heart Association 5, 6
Statin therapy effects: Prolonged statin therapy may have procalcific effects on coronary atheromas and can increase CAC, so interpretation of serial CACS should account for statin use, according to the Journal of Internal Medicine 7
Cost considerations: Repeat CAC testing is generally considered inappropriate by some guidelines and may not be covered by insurance, so clinical utility must justify the expense, as suggested by the American Academy of Family Physicians 8

In asymptomatic adults aged 40‑75 years whose 10‑year ASCVD risk is intermediate (7.5‑20 %) or borderline (5‑7.5 %) and for whom the decision to start statin therapy remains uncertain, a single CAC scan is recommended to aid risk re‑classification. 9, 10

CAC scoring quantifies the burden of coronary atherosclerosis and provides prognostic information that guides the choice and intensity of initial preventive therapies (e.g., statins, lifestyle measures). 9, 10

No prospective randomized controlled trials have demonstrated that serial CAC scoring improves cardiovascular outcomes; therefore, routine repeat scanning is not evidence‑based. 9, 10

CAC scoring should be used as a one‑time risk‑stratification tool; repeat scans are reserved only for selected high‑risk scenarios (e.g., patients with diabetes, those with an initial CAC 100‑400 and suboptimal LDL‑C control, or individuals with CAC = 0 who retain strong risk factors). In such cases, repeat imaging may be considered at 3‑5‑year intervals only when the results are likely to change management decisions. 9, 10